The party shows no sign of stopping
It seems the biotech industry is still enjoying the dolce vita. Many doubted it could continue, but all the signs are showing that it has. Drug pricing has come out unscathed, while M&As seem to be safeguarded after the US government appears to have ceased its tax-law changes on them. To the contrary, investors are still hungry for all things biotech, with the industry’s valuations fluctuating at an impressive rate in 2015. So much so that 2015 is showing signs that it is to welcome as many as 50 new drugs to the market by year’s end, with a fifth-year sales forecast of a staggering $18.6bn.
Continue Reading →
Pharma and Biotech in 2015 was last modified: January 11th, 2016 by
A rapidly changing industry landscape
The first half of 2015 has seen both positive and negative influences come to light for the medtech industry: stock exchange pressures from poor financial results, and diminishing venture capitalist funding for new businesses are just a few of the headaches coming to prominence; conversely, there are some rays of light: the market has seen considerable consolidation with $83bn-worth of mergers already registered. Also the FDA is increasing its level of approvals and overall collaboration with medtech firms (more innovative new products than ever are now likely to make it onto the market), while the medtech IPO market seems to be stabilizing. Continue Reading →
Medtech in 2015 was last modified: December 17th, 2015 by
What does the future hold for the life sciences sector? For the pharmaceutical, biotechnology, and medical technology industries 2014 and the rest of the decade should be a time full of new challenges and new opportunities alike, according to Deloitte’s 2014 global life sciences report.* Continue Reading →
The outlook for Global Life Sciences in 2014… and beyond was last modified: March 26th, 2014 by
The IMS Institute for Healthcare Informatics predicts that annual global spending on medicines will reach nearly $1.2 trillion by 2016, as the impact of emerging markets, generic drugs and biologics begins to be felt.
Continue Reading →
Global Spending on Medicines – Past, Present and Future was last modified: March 26th, 2014 by
According to EvaluatePharma’s World Preview 2013 report *, the past two years have seen one significant negative development (the fact that in dollar terms, worldwide prescription drug sales fell due to a loss of patent protection on a number of popular brands and fiscal austerity measures in Europe) and a host of positive developments that bode well for the future (a massive number of new drug approvals, biological products that will support future sales growth and improvements in research and development productivity.) Continue Reading →
The Pharmaceutical industry: What has been, and what is to come was last modified: March 26th, 2014 by